BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 2664042)

  • 1. Results of a modified WHO regimen in highly bacilliferous BL/LL patients.
    Katoch K; Ramu G; Ramanathan U; Sengupta U; Sreevatsa ; Sharma VD; Shivannavar CT; Katoch VM
    Int J Lepr Other Mycobact Dis; 1989 Jun; 57(2):451-7. PubMed ID: 2664042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and bacteriological progress of highly bacillated BL-LL patients discontinuing treatment after different periods of MDT.
    Katoch K; Natarajan M; Bagga A; Katoch VM
    Int J Lepr Other Mycobact Dis; 1991 Jun; 59(2):248-54. PubMed ID: 2071982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Follow up of BL/LL patients on a slightly modified WHO regimen of multidrug therapy.
    Katoch K; Ramu G; Ramanathan U; Sengupta U; Sreevatsa
    Indian J Lepr; 1987; 59(1):36-43. PubMed ID: 3611859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 10-12 years follow-up of highly bacillated BL/LL leprosy patients on combined chemotherapy and immunotherapy.
    Katoch K; Katoch VM; Natrajan M; Sreevatsa ; Gupta UD; Sharma VD; Shivanavar CT
    Vaccine; 2004 Sep; 22(27-28):3649-57. PubMed ID: 15315844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of bacilliferous BL/LL cases with combined chemotherapy and immunotherapy.
    Katoch K; Katoch VM; Natrajan M; Bhatia AS; Sreevatsa ; Gupta UD; Sharma VD; Shivannavar CT; Patil MA; Bharadwaj VP
    Int J Lepr Other Mycobact Dis; 1995 Jun; 63(2):202-12. PubMed ID: 7602215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Daily multidrug therapy for leprosy; results of a fourteen-year experience.
    de Carsalade GY; Wallach D; Spindler E; Pennec J; Cottenot F; Flageul B
    Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):37-44. PubMed ID: 9207752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Controlled clinical trial of two multidrug regimens with and without rifampin in highly bacilliferous BL/LL south Indian patients: a five-year report.
    Thomas A; Balakrishnan A; Nagarajan M; Prabhakar R; Tripathy SP; Christian M; Somasundaram PR
    Int J Lepr Other Mycobact Dis; 1990 Jun; 58(2):273-80. PubMed ID: 2198314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A case of relapse with drug-susceptible M. leprae after multidrug therapy.
    Constant-Desportes M; Guelpa-Lauras CC; Carolina JC; LĂ©oture A; Grosset JH; Sansarricq H
    Int J Lepr Other Mycobact Dis; 1991 Jun; 59(2):242-7. PubMed ID: 2071981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relapse as histoid leprosy after receiving multidrug therapy (MDT); a report of three cases.
    Shaw IN; Ebenezer G; Rao GS; Natrajan MM; Balasundaram B
    Int J Lepr Other Mycobact Dis; 2000 Sep; 68(3):272-6. PubMed ID: 11221089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical trial of pefloxacin and ofloxacin in the treatment of lepromatous leprosy.
    Grosset JH; Ji BH; Guelpa-Lauras CC; Perani EG; N'Deli LN
    Int J Lepr Other Mycobact Dis; 1990 Jun; 58(2):281-95. PubMed ID: 2198315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bacillaemia in leprosy and effect of multidrug therapy.
    Chatterjee G; Kaur S; Sharma VK; Vaishnavi C; Ganguly NK
    Lepr Rev; 1989 Sep; 60(3):197-201. PubMed ID: 2682105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of three-year multidrug therapy in multibacillary leprosy patients.
    Li W; Ye G; Yang Z; Tao M; Luo J; Wang C; Ji F
    Proc Chin Acad Med Sci Peking Union Med Coll; 1990; 5(1):37-40. PubMed ID: 2371263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Viability of Mycobacterium leprae in lepromatous patients after five years of dapsone monotherapy supplemented with two years of multidrug therapy.
    Sivaprasad N; Snehalatha S; Lobo D; Aschhoff M; Job CK
    Indian J Lepr; 1995; 67(4):427-33. PubMed ID: 8849919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative evaluation of immunotherapeutic efficacy of BCG and mw vaccines in patients of borderline lepromatous and lepromatous leprosy.
    Narang T; Kaur I; Kumar B; Radotra BD; Dogra S
    Int J Lepr Other Mycobact Dis; 2005 Jun; 73(2):105-14. PubMed ID: 16830653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Once monthly rifampicin (1200 mg) plus daily dapsone (100 mg) and clofazimine (100 mg) in the initial treatment of lepromatous leprosy.
    Chandorkar AG; Burte NP; Gade RK; Bulakh PM
    Indian J Lepr; 1984; 56(1):63-70. PubMed ID: 6384381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two microbiological relapses in a patient with lepromatous leprosy.
    Chakma JK; Girdhar A; Natrajan M; Kumar A; Girdhar BK
    Lepr Rev; 2008 Sep; 79(3):331-4. PubMed ID: 19009984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of rhuIFN-gamma treatment in multibacillary leprosy patients.
    Sampaio EP; Malta AM; Sarno EN; Kaplan G
    Int J Lepr Other Mycobact Dis; 1996 Sep; 64(3):268-73. PubMed ID: 8862260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Superiority of the neonatally thymectomized Lewis rat (NTLR) to monitor a clinical trial in lepromatous leprosy of the two regimens of rifampin and dapsone.
    Gelber RH; Humphres RC; Fieldsteel AH
    Int J Lepr Other Mycobact Dis; 1986 Jun; 54(2):273-83. PubMed ID: 3522770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two multidrug fixed-dosage treatment regimens with multibacillary leprosy patients.
    Gallo ME; Alvim MF; Nery JA; Albuquerque EC; Sarno EN
    Indian J Lepr; 1996; 68(3):235-45. PubMed ID: 8889609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pyrazinamide as a part of combination therapy for BL and LL patients--a preliminary report.
    Katoch K; Sreevatsa ; Ramanathan U; Ramu G
    Int J Lepr Other Mycobact Dis; 1988 Mar; 56(1):1-9. PubMed ID: 2453596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.